EUVIMEDEUVIMED entdecken
Crossref

Study of AmpC β-Lactamase Producing Pseudomonas Aeruginosa from Clinical Samples in Tertiary Care Centre

Ashlesha A. Pachakar, Dr. Harsha V. Patil

International Journal of Drug Delivery Technology · 13.03.2026 · 16 (8s)

DOI: 10.25258/ijddt.16.8s.35 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 13.03.2026. Verfasst von Ashlesha A. Pachakar und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In rural Indian hospitals, limited surveillance, inadequate diagnostics, and antibiotic misuse hinder AMR control; this study evaluated Pseudomonas aeruginosa (P. aeruginosa) isolation, antimicrobial susceptibility, and AmpC β-lactamase prevalence. A total of 187 P. aeruginosa isolates obtained from 55 clinical samples were analysed during this study. The overall prevalence of AmpC β-lactamase production was 33.16%. Our study’s AmpC prevalence remained within the upper range of Indian reports, higher than earlier low-prevalence reports with resistance burden. Male predominance was observed, with high AmpC prevalence in ICU and urine isolates, and the highest number of isolates from patients aged 41–60 years (38.75%). A high prevalence of AmpC β-lactamase–producing P. aeruginosa was detected, especially in ICU and urine isolates, with widespread resistance to both β-lactam and non-β-lactam antibiotics. Maximum resistance was noted against cefoxitin (100%), followed by piperacillin (52.5%), ciprofloxacin, ceftazidime, and meropenem (each 51.25%). The isolates showed the best response to piperacillin–tazobactam (61.25%), followed by imipenem and amikacin (56.25% each) and aztreonam (51.25%). In contrast, very low sensitivity was observed to ceftazidime (16.1%) and piperacillin–tazobactam (8.5%). AmpC producers were isolated from urine samples (25%) and ICU patients (32.26%). The cefoxitin–cloxacillin double-disk synergy test showed the highest detection rate (63.75%), followed by the disk approximation test (48.75%) and the boronic acid disk test (45%). These findings highlight the need for routine AmpC screening, stronger antimicrobial stewardship, and effective infection control in both tertiary and rural healthcare settings in India to limit the spread of multidrug-resistant P. aeruginosa.

Zitieren

APA

Pachakar, A. A., & Patil, D. H. V. (2026). Study of AmpC β-Lactamase Producing Pseudomonas Aeruginosa from Clinical Samples in Tertiary Care Centre. International Journal of Drug Delivery Technology, 16(8s). https://doi.org/10.25258/ijddt.16.8s.35

Vancouver

Pachakar AA, Patil DHV. Study of AmpC β-Lactamase Producing Pseudomonas Aeruginosa from Clinical Samples in Tertiary Care Centre. International Journal of Drug Delivery Technology. 2026;16(8s). doi:10.25258/ijddt.16.8s.35

BibTeX
@article{Pachakar2026,
  author = {Pachakar, Ashlesha A. and Patil, Dr. Harsha V.},
  title = {Study of AmpC β-Lactamase Producing Pseudomonas Aeruginosa from Clinical Samples in Tertiary Care Centre},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {8s},
  doi = {10.25258/ijddt.16.8s.35}
}
Kostenlos starten →